HCW Biologics(US:HCWB) Benzingaยท2025-09-12 05:27Group 1 - HCW Biologics Inc. shares surged 102.72% to $6.73 in after-hours trading following the announcement of successful development of second-generation T-cell engagers targeting solid tumors [1] - The company has developed new T-cell engagers targeting tissue factor for treating pancreatic cancer and glioblastoma using its TRBC platform technology [2] - The advancement aims to address major issues with earlier T-cell engagers, including manufacturing difficulties, safety concerns, and weak results against solid tumors [3] Group 2 - HCW Biologics reported 100% survival rates in tumor-bearing mice models for its lead candidate, while untreated mice showed zero survival [4] - Non-human primate studies indicated that the treatment was well-tolerated at efficacious dose levels without inducing cytokine release syndrome [4] - The CEO stated that preclinical studies show potential for significant tumor shrinkage with the second-generation T-cell engagers [5] Group 3 - The company plans to collaborate with financially robust corporations for development, aiming to capitalize on a market where T-cell engagers generate billions in annual sales [5] - Over the past year, HCW Biologics experienced significant stock fluctuations, peaking at $49.60 on November 18, 2024, and recently dropping to $3.32 [6] - The stock has averaged 3.06 million shares traded daily over the year, reflecting a loss of 85.46% [6]